Onconetix, Inc.
Onconetix is a commercial-stage biotechnology company focused on men’s health and oncology. It is headquartered in Cincinnati, Ohio, and is currently focused on commercializing Proclarix, a protein-based blood test for prostate cancer intended to help doctors and patients assess unclear PSA test results and support decisions about whether a biopsy is needed. Proclarix is CE-marked and for sale in Europe, and Onconetix anticipates marketing it in the United States as a lab-developed test through a license agreement with LabCorp. The company relies on third parties to manufacture the test. Onconetix makes money from sales of Proclarix. It abandoned commercialization of ENTADFI, an FDA-approved pill for benign prostatic hyperplasia, and no longer has inventory of the product. The company was founded in October 2018 and shifted its focus to men’s health and oncology after deprioritizing its vaccine programs.
No SEC Form 4 filings for $ONCO in the last 30 days.
See all $ONCO insider activity →Oncopeptides AB completed a directed issue of 50 million ordinary shares, increasing total shares to 445.3 million. The company's share capital is now SEK 49.5 million. The move formalizes a previously announced share issue, providing new capital for the biotech firm.
Onconetix (ONCO) announced that its acquisition target, Realbotix, launched Echo humanoid robots priced at $11,950 (Tabletop) and $59,950 (Full Body), with 250 units planned for H2 2027 delivery. The acquisition is pending approvals and is an all-stock deal.
Onconetix, Inc. (ONCO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Onconetix Announces Reverse Stock Split CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company’s outstand
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning ONCO (Onconetix, Inc.). Coverage has been balanced: 1 bullish, 6 neutral, and 1 bearish.
Recent ONCO coverage spans corporate actions, mergers & acquisitions and technology.
The share issuance dilutes equity and may pressure the stock lower.
The news may lift Onconetix as the acquisition progresses and new product revenue potential emerges.
The reverse split will reduce share count and raise the per‑share price, likely causing modest buying pressure as the stock becomes more attractive to institutional investors.
Reverse split reduces share count, may improve price perception and affect liquidity.
The incremental financing may slightly improve Realbotix's cash position but has limited immediate impact on Onconetix's valuation.
AlphAI scores every news story that mentions ONCO with an AI model for sentiment and relevance, and aggregates insider trades from Onconetix, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Oncopeptides AB completed a directed issue of 50 million ordinary shares, increasing total shares to 445.3 million. The company's share capital is now SEK 49.5 million. The move formalizes a previously announced share issue, providing new capital for the biotech firm.
1 min readOnconetix (ONCO) announced that its acquisition target, Realbotix, launched Echo humanoid robots priced at $11,950 (Tabletop) and $59,950 (Full Body), with 250 units planned for H2 2027 delivery. The acquisition is pending approvals and is an all-stock deal.
1 min readOnconetix, Inc. (ONCO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Onconetix Announces Reverse Stock Split CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company’s outstand
1 min readOnconetix, Inc. (ONCO) announced a 1-for-10 reverse stock split, effective November 6, 2026. Outstanding shares will reduce from ~5.89M to ~588.68K, with cash for fractional shares. Trading continues under 'ONCO' on Nasdaq. Ownership percentages remain unchanged.
1 min readOnconetix, Inc. (ONCO) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 22, 2026, Onconetix, Inc. (the “Company”) made an additional advance of $500,000 to Realbotix, LLC (“Realbotix”) pursuant to that certain Grid Promissory Note, dated September 11, 2026 (the “Note”), previously disclosed in the Company’s Current
1 min readOnconetix (NASDAQ:ONCO) advanced $500,000 to Realbotix, its acquisition target, under a $5M non-interest-bearing facility. Total outstanding is $3M. The loan will be canceled upon acquisition closing, reducing required cash. The deal needs shareholder and regulatory approvals. Realbotix is a subsidiary of Realbotix Corp. (TSX-V:XBOT).
2 min readOncopeptides AB (publ) plans a SEK 100 million directed share issue to fund glioblastoma program development. The company aims to use proceeds for clinical studies and CMC activities. Largest shareholder HealthCap VIII LP will subscribe for SEK 10 million. The issue is expected to complete by 14 October 2026.
4 min readOncopeptides AB (publ) will host a webcast on Oct 12 after reporting positive interim data for OP-701, showing its PDC platform penetrated the blood-brain barrier in glioblastoma patients. The company did not provide full efficacy or safety data.
1 min readOncopeptides reported initial data from its INSULA WoO study, showing blood-brain-barrier penetration and good tolerability in the first three patients with glioblastoma. The company is recruiting up to 10 patients. This is early-stage data, not efficacy results.
1 min readOnconetix Inc. (NASDAQ: ONCO) stock rose 14.58% on news of its AI robotics deal with Realbotix, backed by SRX Global. The company's stock has been volatile, trading between $0.64 and $1.40 recently. ONCO has small revenue ($0.8M) and steep losses but holds $5.9M in cash. The Realbotix acquisition aims to pivot into AI and defense sectors, with a pilot project underway. ONCO provided $2.5M in bridge financing, with a 12% interest penalty if the deal fails.
2 min read
